Bluesail Medical and Wanhua Chemical Forge Exclusive Partnership to Launch High-Performance Polyurethane Gloves, Poised to Reshape Global Disposable Glove Market

Following PVC, latex, and nitrile gloves, polyurethane (PU) gloves are poised to capture a share of the annual multi-hundred-billion-unit disposable nitrile glove market, thanks to their qualitative leaps in breathability (reducing sweat buildup), puncture resistance, high elasticity, hypoallergenic properties, and skin-friendliness, thereby reshaping the current landscape of the disposable glove industry.

Bluesail Medical, the leading glove manufacturer, recently signed a strategic cooperation agreement with Wanhua Chemical, the global leader in the polyurethane industry, and held an unveiling ceremony for their joint innovation laboratory. The two parties will deepen their collaboration, focusing on medical device fields such as disposable polyurethane gloves, medical catheters, PEBA, nylon, and PC.

In the field of polyurethane gloves, after five years of collaboration, both parties have achieved product qualification rates and online stability that meet the requirements for mass production. The physical properties of the products, including alcohol resistance, have met the standards. In terms of market performance, the export market is gradually gaining recognition, with some orders already secured in Europe and America, while domestic sales are steadily increasing.

Bluesail Medical and Wanhua Chemical have joined hands since 2019 to explore the application of polyurethane in the glove sector. After more than five years of close collaboration and relentless efforts, the two teams successfully launched a new line of high-performance polyurethane gloves this August. Moving forward, both parties will continue to cooperate to enhance product performance, reduce production costs, jointly promote market adoption, and drive the establishment of industry standards.

This collaboration constitutes an exclusive partnership between the two parties. Wanhua Chemical will leverage its stable supply capabilities in the field of polyurethane materials to provide high-quality raw materials to Bluesail Medical, ensuring optimal production efficiency and cost control for gloves and other medical consumables. Meanwhile, Bluesail Medical’s global sales network, brand influence, and manufacturing capabilities will open up broader market opportunities for the jointly developed products, driving rapid growth in sales volume.

Bluesail Medical is a global leader in the medical glove industry, with sales channels covering more than 130 countries worldwide and over 300 global partners, including internationally renowned pharmaceutical distributors. Its cooperative channels are stable, and user stickiness is strong. In the domestic market, the company has established business relationships with more than 2,700 hospitals. The company’s export market share of disposable PVC gloves ranks first globally, while its nitrile glove exports account for more than 21% of China’s total customs export volume, securing a top-three position in the global market. Furthermore, this June, Bluesail Medical secured a $200 million investment from Thai industrial investor HKG. This strategic investment provides financial support for the future development of polyurethane gloves.

Polyurethane is a polymer material characterized by high density, superior abrasion resistance, high elasticity, and excellent barrier properties, making it widely used in the pharmaceutical, electronics, textile, and aerospace industries. Currently, the global disposable glove market primarily consists of nitrile, PVC, and latex gloves, with applications spanning healthcare, food service, electronics, industrial, and consumer sectors. Global demand for disposable gloves continues to rise. Due to their outstanding comprehensive performance and relatively reasonable pricing, nitrile gloves have experienced rapid growth, registering a compound annual growth rate (CAGR) of 18% from 2017 to 2021, and currently maintaining a CAGR of approximately 10%. According to data released in the "2023 White Paper on the Development of China's Disposable Nitrile Glove Industry," the share of nitrile gloves in global sales volume increased from 31.6% in 2017 to 35.6% in 2022, and is projected to further rise to 37.1% by 2025, positioning nitrile gloves as the core product driving future growth in the disposable glove market.

Mass production of polyurethane gloves is expected to disrupt the global glove industry landscape. According to reports, in terms of performance, polyurethane gloves have no significant drawbacks compared to the commonly available nitrile, PVC, and latex gloves on the market. Moreover, they represent a qualitative leap in puncture resistance, high elasticity, and hypoallergenic properties. As a result, they are poised to become strong competitors to nitrile gloves, demonstrating their market competitiveness within an annual demand spanning hundreds of billions of units.

Bluesail Medical and Wanhua Chemical are not limited to the single product category of medical gloves; instead, they focus on the in-depth optimization and synergistic development of the entire industrial chain. The two parties have established a Joint Innovation Laboratory dedicated to advancing scientific research and continuous technological innovation. Their efforts aim not only to iteratively upgrade polyurethane gloves but also to develop innovative products featuring enhanced comfort, superior durability, and optimized protective performance.

Bluesail Medical possesses globally leading technologies and products in the high-end segment of medical consumables, such as cardiovascular interventional products. Wanhua Chemical has established a comprehensive portfolio of biomedical materials covering engineering plastics, commodity plastics, elastomers, polyurethanes, and medical supplies, breaking foreign monopolies in the field of high-performance materials and achieving independent intellectual property rights. By leveraging Bluesail Medical’s strengths in combination with Wanhua Chemical’s innovation capabilities in new material research and development, the two companies are poised to develop next-generation innovative material products with superior performance and more controllable costs. This collaboration promises to benefit patients while creating new business growth drivers for both parties.